Cite
HARVARD Citation
Wrangle, J. et al. (2018). ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet oncology. 19 (5), pp. 694-704. [Online].